Nafazatrom is an orally active cardioprotective agent that protects the myocardium against ischemic injury; it reduces infarct size and the incidence of arrhythmias, and preserves ischemic myocardial function without affecting hemodynamic parameters in a canine ischemia-reperfusion model. Its cardioprotective effects are likely mediated through inhibition of neutrophil function and cellular infiltration, as evidenced by its dose-dependent inhibition of neutrophil aggregation, superoxide anion generation, and arachidonic acid metabolism in vitro, with minor inhibition of β-glucuronidase release, while showing no significant effect on platelet aggregation or arachidonic acid metabolism.